Literature DB >> 21901982

Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane.

K H Singh1, U A Shinde.   

Abstract

Various efforts have been made to improve the bioavailability and to prolong the residence time of eye drops. Drug loaded polymeric nanoparticles offer several favorable biological properties. Thus, brimonidine tartrate (BT) loaded chitosan (CS) nanoparticles were prepared by inducing the ionic gelation upon addition of sodium tripolyphosphate (TPP). Nanoparticles were characterized by TEM, SEM, particle size, polydispersity index (PI), DSC, IR, entrapment efficiency which gave an insight of physicochemical interaction that influenced the CS nanoparticle formation and entrapment of BT. In vitro release of BT nanoparticle showed sustained release over the period of 4 h in saline phosphate buffer pH 7.4. Both placebo and BT loaded nanoparticles had a mean particle size range of about 270-370 nm with PI less than 0.5. DSC studies demonstrated structural interactions between BT, TPP and CS matrix. Entrapment efficiency of the CS nanoparticles ranged from 36-49% depending on the CS:TPP weight ratio. In vivo studies confirmed a significant sustained effect of BT nanoparticles compared to conventional eye drops. These results suggest that BT loaded CS nanoparticles could help to reduce dosage frequency by sustained drug release in the treatment of glaucoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901982

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  9 in total

1.  Nanoparticles in the ocular drug delivery.

Authors:  Hong-Yan Zhou; Ji-Long Hao; Shuang Wang; Yu Zheng; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

Review 2.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

Review 3.  Nanoparticles for the treatment of glaucoma-associated neuroinflammation.

Authors:  Lidawani Lambuk; Nurfatihah Azlyna Ahmad Suhaimi; Muhammad Zulfiqah Sadikan; Azliana Jusnida Ahmad Jafri; Suhana Ahmad; Nurul Alimah Abdul Nasir; Vuk Uskoković; Ramlah Kadir; Rohimah Mohamud
Journal:  Eye Vis (Lond)       Date:  2022-07-02

4.  Novel topical ophthalmic formulations for management of glaucoma.

Authors:  Mohammed M Ibrahim; Abd-Elgawad H Abd-Elgawad; Osama A Soliman; Monica M Jablonski
Journal:  Pharm Res       Date:  2013-06-15       Impact factor: 4.200

5.  Natural Bioadhesive Biodegradable Nanoparticle-Based Topical Ophthalmic Formulations for Management of Glaucoma.

Authors:  Mohammed Mostafa Ibrahim; Abd-Elgawad Helmy Abd-Elgawad; Osama Abd-Elazeem Soliman; Monica M Jablonski
Journal:  Transl Vis Sci Technol       Date:  2015-06-30       Impact factor: 3.283

6.  Thermosensitive hydrogel based on chitosan and its derivatives containing medicated nanoparticles for transcorneal administration of 5-fluorouracil.

Authors:  Angela Fabiano; Ranieri Bizzarri; Ylenia Zambito
Journal:  Int J Nanomedicine       Date:  2017-01-16

7.  Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits.

Authors:  Ana Marie L Rubenicia; Leo D P Cubillan; Victor Arni D P Sicam; Allan Patrick G Macabeo; Oliver B Villaflores; Agnes L Castillo
Journal:  Transl Vis Sci Technol       Date:  2021-04-01       Impact factor: 3.283

8.  Sustained release of brimonidine from BRI@SR@TPU implant for treatment of glaucoma.

Authors:  Yujin Zhao; Chang Huang; Zhutian Zhang; Jiaxu Hong; Jianjiang Xu; Xinghuai Sun; Jianguo Sun
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

9.  Development of dorzolamide loaded 6-o-carboxymethyl chitosan nanoparticles for open angle glaucoma.

Authors:  Ujwala Shinde; Mohammed Hadi Ahmed; Kavita Singh
Journal:  J Drug Deliv       Date:  2013-10-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.